Quintrio
Home

Stock overview

Apollomics Inc. Class A Ordinary Shares

APLM

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $16.61 – $18.25
Volume 8,600
Market cap $52M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for APLM.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for APLM.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Apollomics, Inc. Company Operational Continuity Update

Apollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.

GlobeNewswire Inc.

Nasdaq Halts Apollomics Inc., Ltd.

Nasdaq Stock Market halted trading for Apollomics Inc. on September 17, 2025, at 14:37:17 Eastern Time, requesting additional information from the company.

GlobeNewswire Inc.

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 25, 20241-for-100reverse split